— Presentation entitled “BMB-101: A selective 5-HT2C agonist in clinical trials with therapeutic utility” — — First-in-human Phase 1 trial for lead program, BMB-101, is underway in Australia — VANCOUVER, British Columbia, April 10, 2023 (GLOBE NEWSWIRE) — Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) (“Bright Minds” or the “Company”), a biotechnology company focused on developing novel…


Previous articlePsychedelic Bulletin #135: A Misguided MDMA Price-Fixing Effort; Psilocybin Study’s Lukewarm Results; Dutch Government Forms MDMA Commission; Trouble at Empyrean?
Next articleCOMPASS Pathways to participate in upcoming 22nd Annual Needham Virtual Healthcare Conference